Suzanne Hendrix

Efficient use of open label extension data

Time saved with Alzheimer’s disease therapeutics

Time saved in Alzheimer’s disease in Phase III trial of donanemab

Measuring cognitive impairment in early Alzheimer’s disease

Assessing clinical meaningfulness with ‘time saved’ in Alzheimer’s disease

The power of composite tests to track Alzheimer’s disease progression

Trends in the use of surrogate biomarkers during clinical trials

Futility analysis in clinical trials: practical and ethical considerations

Symptomatic versus disease modifying treatments

Distinguishing between disease modifying and symptomatic effects in clinical trials